Kwality Pharmaceuticals Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Kwality Pharmaceuticals Ltd filed with BSE on 21 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Kwality Pharmaceuticals reported Q4 FY26 revenue of Rs157.1 crore, up 35.8% year-on-year, and full-year FY26 revenue of Rs503 crore, up nearly 36% from Rs370 crore in FY25. EBITDA margins expanded from 22% to 24% and profit after tax grew 69% to Rs67 crore, with management citing improved cash conversion cycle and recovery of delayed Middle East receivables. Management reiterated FY27 targets of Rs650-700 crore revenue and Rs100 crore PAT, alongside a longer-term aspiration of Rs1,000 crore revenue by FY29.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: INR157.1 crores (Q4 FY26)
p. 3
“In quarter four of FY '26, our revenue grew 35.8% to INR157.1 crores compared to INR116 crores for the same quarter last year.”
Aditya Arora, page 3 of the filed PDF · View the filing
Revenue: INR503 crores (FY26)
p. 3
“For the full year, revenue increased to INR503 crores from INR370 crores in FY25, reflecting a strong growth of nearly 36%.”
Aditya Arora, page 3 of the filed PDF · View the filing
EBITDA margin: 24% (FY26)
p. 3
“The EBITDA margins expanded from 22% to 24% while profit after tax grew 69% to INR67 crores from INR40 crores last year.”
Aditya Arora, page 3 of the filed PDF · View the filing
Profit after tax: INR67 crores (FY26)
p. 3
“The EBITDA margins expanded from 22% to 24% while profit after tax grew 69% to INR67 crores from INR40 crores last year.”
Aditya Arora, page 3 of the filed PDF · View the filing
PAT margin: 13.4% (FY26)
p. 3
“The PAT margins improved from 10.8% to 13.4%, driven by better operation efficiencies, improved realization, and disciplined cost management.”
Aditya Arora, page 3 of the filed PDF · View the filing
Cash conversion cycle: 170 days (FY26)
p. 3
“we improved our cash conversion cycle from 208 days to 170 days and have already recovered nearly 30% of delayed receivables from Middle Eastern markets.”
Aditya Arora, page 3 of the filed PDF · View the filing
Oncology revenue: roughly close to INR100 crores (FY26)
p. 4
“So, Deepakji, the revenue was roughly close to INR100 crores in FY26 for oncology.”
Aditya Arora, page 4 of the filed PDF · View the filing
Capacity utilization (oncology): 65% (FY26)
p. 9
“That has caused a, you know, increase in utilization of capacity from 30%, 35% to simply to 65%.”
Aditya Arora, page 9 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue — INR650 crores · FY27
stated firmly by Aditya Arora
p. 3
“Looking ahead, we remain confident of achieving our FY27 goals of INR650 crores in revenue and INR100 crores PAT in FY27, while continuing our journey toward long-term aspiration of INR1,000 crores revenue by FY29.”
Aditya Arora, page 3 of the filed PDF · View the filing
Revenue — INR650 crores to INR700 crores · FY27
stated conditionally by Aditya Arora
p. 4
“So, we believe that INR650 crores is a very, very achievable number, but this number could increase considering if we get more registrations or queries from the ministry and the registration happens in the timely manner.”
Aditya Arora, page 4 of the filed PDF · View the filing
Oncology revenue — INR300 crores · FY29
stated as an aspiration by Aditya Arora
p. 4
“So, this number we are projecting to increase by up to INR300 crores by FY29.”
Aditya Arora, page 4 of the filed PDF · View the filing
Revenue — INR800 crores to INR850 crores · FY28
stated as an aspiration by Aditya Arora
p. 5
“Roughly around INR800 crores to INR850 crores, sir.”
Aditya Arora, page 5 of the filed PDF · View the filing
EBITDA margin — 30% · FY29
stated as an aspiration by Aditya Arora
p. 5
“Our target is around FY29 INR1,000 crores mean 30% EBITDA margins.”
Aditya Arora, page 5 of the filed PDF · View the filing
Unit 6 hormone commercialization — WHO GMP and commercialization in ROW market · before November
stated firmly by Aditya Arora
p. 5
“So, we believe that before November, we'll try to get the WHO GMP and do the commercialization in the ROW market.”
Aditya Arora, page 5 of the filed PDF · View the filing
Unit 6 hormone revenue — INR150 crores · before FY29
stated as an aspiration by Aditya Arora
p. 6
“Sir, it totally depends upon the registrations we do in the high regulated, but as of now if we consider only unregulated and semi-regulated, we target at achieving INR150 crores before FY29.”
Aditya Arora, page 6 of the filed PDF · View the filing
Capex — roughly INR90 crores · FY27
stated firmly by Aditya Arora
p. 6
“So, FY27, we would do roughly around INR90 crores and another INR90 crores to INR100 crores in FY28.”
Aditya Arora, page 6 of the filed PDF · View the filing
Q1 FY27 revenue — INR150 crores to INR160 crores · Q1 FY27
stated firmly by Aditya Arora
p. 7
“So, probably the Q1 for FY27 will be the same as Q4 of FY26. It will be around INR150 crores -- between INR150 crores to INR160 crores.”
Aditya Arora, page 7 of the filed PDF · View the filing
Q4 FY27 revenue — cross INR200 crores mark · Q4 FY27
stated as an aspiration by Aditya Arora
p. 7
“And quarter four, our target is that we should cross INR200 crores mark.”
Aditya Arora, page 7 of the filed PDF · View the filing
Gross margin — 52% to 53% · FY27
stated as an aspiration by Aditya Arora
p. 14
“So, when we talk about FY27, we believe that this number should be around -- the gross cost should be around 46% to 47% compared to 49% in the last year.”
Aditya Arora, page 14 of the filed PDF · View the filing
EPO submissions — filing in almost 50 countries · Q4 of FY27
stated firmly by Aditya Arora
p. 17
“But with respect to the filing, the next Q4 of FY27 we are going to make submission in almost 50 countries of erythropoietin.”
Aditya Arora, page 17 of the filed PDF · View the filing
Hormone and biosimilar revenue — INR200 crores · FY29
stated conditionally by Aditya Arora
p. 17
“You can assume INR200 crores revenue from hormone and biologics by FY29.”
Aditya Arora, page 17 of the filed PDF · View the filing
Revenue — INR1,000 crores · FY29
stated as an aspiration by Aditya Arora
p. 21
“So, if this situation doesn't arise, Kwality can smoothly reach a INR1,000 crores mark.”
Aditya Arora, page 21 of the filed PDF · View the filing
Revenue (contingency) — INR800 crores, INR850 crores · FY29
stated conditionally by Aditya Arora
p. 21
“However, to our investors and for our own, I mean, as a keeping biological and hormone as a contingency plan, we believe that if something goes wrong even then we can reach INR800 crores, INR850 crores mark, and additional revenues from hormone and biosimilars can help us cross that INR1,000 crores mark.”
Aditya Arora, page 21 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the number is conservative but achievable, with upside of about Rs50 crore depending on registration timing.
Answered by Aditya Arora
Asked by Deepak Chokhani: Whether the FY27 guidance of Rs650 crore revenue and Rs100 crore PAT is conservative given Q4 annualized figures already imply that.
p. 4
“So, we believe that INR650 crores is a very, very achievable number, but this number could increase considering if we get more registrations or queries from the ministry and the registration happens in the timely manner.”
Aditya Arora, page 4 of the filed PDF · View the filing
Oncology revenue was about Rs100 crore in FY26, projected to grow to Rs150 crore next year and Rs300 crore by FY29.
Answered by Aditya Arora
Asked by Deepak Poddar: What was the oncology revenue mix in FY26 and its trajectory to FY29.
p. 4
“So, Deepakji, the revenue was roughly close to INR100 crores in FY26 for oncology. So, this number we are projecting to increase by up to INR300 crores by FY29.”
Aditya Arora, page 4 of the filed PDF · View the filing
Total capex of about Rs260-270 crore across hormones, oncology expansion, biosimilars and R&D, with Rs90 crore in FY27 and Rs90-100 crore in FY28.
Answered by Aditya Arora
Asked by Utkarsh Somaiya: How will capex look in FY27 and FY28 across the four growth projects.
p. 6
“So, sir, for hormones, oncology expansion, biosimilar with clinical trials and the R&D and the bioequivalence what we have to do, all these four projects roughly the capex was around INR260 crores to INR270 crores, out of which INR46 crores capex we have already done in FY26.”
Aditya Arora, page 6 of the filed PDF · View the filing
About 40% of the Rs60-70 crore stuck amount had been recovered, with the rest expected by June or July.
Answered by Aditya Arora
Asked by Vineet: How much was recovered from delayed Middle East receivables after March 31.
p. 11
“So, INR60 crores to INR70 crores was stuck in last one and a half to two quarters, but now I think we have realized 40% of it we have already realized and maybe in June, we'll -- June or July, we'll realize the complete amount.”
Aditya Arora, page 11 of the filed PDF · View the filing
Alteplase was dropped due to limited patient availability in India and replaced with Pembrolizumab.
Answered by Aditya Arora
Asked by Manan Vandur: Status of the Alteplase product mentioned in past presentations.
p. 12
“So, Alteplase we had to drop, sir, considering the number of patients who are not available in India.”
Aditya Arora, page 12 of the filed PDF · View the filing
Management attributed the decline partly to war-related cost increases and expects gross margins to recover to 51-52% in coming quarters.
Answered by Aditya Arora
Asked by Abhijeet: What caused the decline in gross margin this quarter and outlook.
p. 18
“Basically, it could be the -- I think, it could be the reason for the increase cost due to war situation also for few of the products.”
Aditya Arora, page 18 of the filed PDF · View the filing
Management named international war/geopolitical situations as the main risk that could delay payment and delivery cycles.
Answered by Aditya Arora
Asked by Ashish Soni: What are the major risks or challenges for the FY29 business plan.
p. 21
“So, basically, sir, if there is no such war situation, because if you see neither the India-Pakistan war, neither floods, nor any other, I mean such situation has hampered Kwality's business as of now, but this international war situation has caused a little delay in the payment cycle and delivery cycle.”
Aditya Arora, page 21 of the filed PDF · View the filing
Risks flagged
Geopolitical disruptions affecting working capital cycles and receivables from Middle East markets
p. 3
“Despite temporary geopolitical disruptions impacting working capital cycles, we improved our cash conversion cycle from 208 days to 170 days and have already recovered nearly 30% of delayed receivables from Middle Eastern markets.”
Aditya Arora, page 3 of the filed PDF · View the filing
Change in European Annexure 1 guidelines increasing manufacturing changeover timelines and capacity utilization pressure
p. 4
“So, probably the challenges which we faced in the last year was that because of the change in the guidelines of Annexure 1, European guidelines, so the timeline of manufacturing and the process of manufacturing change controls and changeovers as per those guidelines, the capacity utilization came down from, I mean, from 35% to 40% to 65%.”
Aditya Arora, page 4 of the filed PDF · View the filing
Disruption in the Strait of Hormuz increasing payment cycle delays
p. 11
“But because of the state situation in the Strait of Hormuz, the payment cycle has increased a lot, but however it has now come down and we have started to realize the payments.”
Aditya Arora, page 11 of the filed PDF · View the filing
Rising dollar/euro rates increasing effective costs though offset so far
p. 15
“Sir, it has been replaced by the increase in dollar rate. So, we couldn't ask much increase in the prices to our customers.”
Aditya Arora, page 15 of the filed PDF · View the filing
Uncertain timelines for biosimilar and hormone regulatory approvals
p. 17
“So, we are not sure about the timelines for registration.”
Aditya Arora, page 17 of the filed PDF · View the filing
War situations such as the India-Pakistan conflict or floods potentially delaying payment and delivery cycles
p. 21
“So, basically, sir, if there is no such war situation, because if you see neither the India-Pakistan war, neither floods, nor any other, I mean such situation has hampered Kwality's business as of now, but this international war situation has caused a little delay in the payment cycle and delivery cycle.”
Aditya Arora, page 21 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.